$1.41+3.7%Nov 13 close
Reported results on November 13, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 14, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $331.8K | $409.3K | -18.92% |
| Profit | -$4.5M | -$4.6M | +2.55% |
| Profit per share | -$1.33 | -$3.18 | +58.18% |
| Free Cash Flow | -$3.9M | -$4.4M | +11.29% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Femasys Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We maintained a lean team and tightly managed resources as we prioritized financing from long-term institutional investors. Closing the $30 million in financing in mid-August 2026 represents an important turning point for Femasys,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Femasys is a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide. The Company is focused on commercializing its fertility portfolio, led by FemaSeed ® Intratubal Insemination, together with complementary diagnostic and sperm preparation products, in the U.S. and key international markets. Femasys is also advancing FemBloc ® , its non-surgical, in-office permanent birth control solution, toward U.S. FDA approval through the ongoing FINALE pivotal trial (NCT05977751). FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025, supporting commercialization through strategic partnerships in select international markets. Femasys’ portfolio is supported by broad intellectual property protection and clinical data demonstrating favorable safety, encouraging effectiveness results, and high patient and practitioner satisfaction. Learn more at www.femasys.com , or follow us on X , Facebook and LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Femasys Inc.’s Item 2.02 8-K filed November 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.